AC-Semax NH2 (10mg) for Sale

All Iron Mountain Labz products are only intended for laboratory research use and are not approved for human consumption.

Overview of AC-Semax NH2

AC-Semax NH2 is a synthetic, C-terminally amidated and N-acetylated analogue of Semax, itself a heptapeptide derivative of the adrenocorticotropic hormone (ACTH) fragment 4–10. The full sequence of AC-Semax NH2 is Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂. This incorporates both N-terminal acetylation and C-terminal amidation, structural modifications that have been investigated in preclinical models for their effect on proteolytic stability and receptor interaction profiles relative to the unmodified parent peptide.

AC-Semax NH2 is classified as a research-grade peptide. It is not approved by the FDA for any therapeutic indication, including neurological, cognitive, or neuroprotective applications, including ingestion, injection, or any form of administration to humans. It is not a dietary supplement, over-the-counter product, or consumer compound of any kind. All research involving AC-Semax NH2 must be conducted strictly within licensed laboratory or institutional settings, restricted to qualified researchers and licensed laboratory institutions. Studies involving animal subjects require IACUC compliance; any clinical investigations require IRB oversight and applicable regulatory approval.

Handling of this compound in laboratory environments should follow standard precautions applicable to bioactive research-grade peptides. Personnel should use appropriate protective equipment, avoid uncontrolled exposure, and adhere to institutional biosafety protocols. No human safety profile has been established for research-grade AC-Semax NH2 formulations.

Chemical Properties

Section	Details
CAS Number	2920938-90-3 (N-Acetyl Semax Amidate, confirmed) Parent Semax CAS (reference): 80714-61-0
Molar Mass	854.97 g/mol
Chemical Formula	C₃₉H₅₄N₁₀O₁₀S
IUPAC Name	N-acetyl-L-methionyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-prolyl-glycyl-L-proline amide
Synonyms	Acetyl Semax Amide; AC-Semax-NH2; N-Acetyl-Semax-NH2; ACTH(4-10) analogue, acetylated/amidated
Peptide Sequence	Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂
Physical Form	Lyophilized powder
Appearance	White to off-white powder
Purity	≥98% (HPLC)
Storage	−20°C, protected from light and moisture; avoid repeated freeze-thaw cycles
Shelf Life	24 months when stored under recommended conditions
Solubility	Soluble in sterile water or aqueous buffer systems (laboratory use)
Classification	Research Use Only (RUO)
PubChem CID	172638603 (N-Acetyl Semax Amidate, confirmed) Parent Semax PubChem CID (reference): 122178
WADA Status	Not listed on WADA 2026 Prohibited List. | Verify via GlobalDRO.com prior to sport | science research use

AC-Semax NH2’s Mechanism of Action in Research Models

AC-Semax NH2 has been investigated in preclinical models in the context of neurotrophic and neuroprotective signaling pathways. Mechanistically, the parent compound Semax and its structural analogues have been observed in experimental systems to interact with the melanocortin receptor system, with investigational interest particularly around MC4R-associated signaling; receptor subtype binding data specific to the AC-NH2 variant remains limited in published preclinical literature.

In in vitro and preclinical animal model settings, Semax analogues have been investigated for their association with upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression at the mRNA and protein level. In rat basal forebrain preparations, specific binding sites for Semax have been identified with a dissociation constant (KD) of approximately 2.4 ± 1.0 nM and a Bmax of 33.5 ± 7.9 fmol/mg protein, suggesting saturable and reversible receptor interaction in that experimental model [Dolotov et al., 2006]. The acetylation and amidation modifications present in AC-Semax NH2 have been studied for their potential to reduce peptide degradation by endopeptidases and aminopeptidases, which has been observed to correlate with extended half-life in experimental plasma stability assays relative to the non-modified peptide.

At the cellular level, preclinical investigations have examined interactions with downstream signaling cascades associated with tropomyosin receptor kinase B (TrkB) pathways, which are mechanistically linked to neurotrophic factor signaling. Observed effects in laboratory settings have included modulation of synaptic plasticity markers in rodent CNS tissue preparations. Findings are not consistent across all models, and the biological activity of the AC-NH2 variant compared to unmodified Semax has not been fully characterized in all relevant preclinical systems. Data remains limited, and no translational conclusions regarding human applicability can be drawn from available preclinical findings.

AC-Semax NH2 Research Findings in Preclinical Models

Preclinical investigations have examined AC-Semax NH2 and its parent compound class in relation to the following areas of laboratory inquiry:

Neurotrophic Factor Modulation:

In rodent CNS tissue models, Semax-class peptides have been investigated for their association with changes in BDNF and NGF gene expression at both the mRNA and protein levels. In the rat hippocampus and frontal cortex, Semax administration in animal models has been observed to produce multidirectional activation of neurotrophin gene expression across brain regions, including hippocampus, frontal cortex, and retinal tissue [Dolotov et al., 2006]. These associations were observed in preclinical rodent models; findings have not been replicated uniformly across all experimental systems.

BDNF Protein Upregulation and Receptor Binding:

In rat basal forebrain preparations, intranasal administration of Semax at 50 and 250 µg/kg bodyweight in rodent models was associated with a measurable increase in BDNF protein levels at 3 hours post-administration, as detected by sandwich immunoenzymatic analysis [Gudasheva et al., 2006]. Binding site characterization indicated the presence of specific, calcium-dependent Semax binding sites in this brain region. These findings were observed in animal model systems and do not establish translational applicability.

Neuroprotective Pathway Involvement:

In preclinical models of CNS stress, Semax-class peptides have been investigated for associations with modulation of inflammatory gene expression and synaptic plasticity markers. Observed effects in laboratory settings included interactions with TrkB-linked downstream cascades in rodent tissue preparations. Data across these models remains variable, and the extent to which AC-Semax NH2’s structural modifications alter these observations relative to the unmodified parent peptide has not been fully characterized in published research.

Note: All findings described above are derived exclusively from preclinical animal and in vitro laboratory studies involving Semax or closely related structural analogues. No peer-reviewed clinical data specific to AC-Semax NH2 as a distinct compound is currently available. These findings do not establish safety, efficacy, or suitability for any human or veterinary application.

Risks & Handling Information

Risk Tier: LOW-MODERATE (Bioactive Research Peptide — CNS-Active Class)

Risk Basis: AC-Semax NH2 is a synthetic melanocortin/neurotrophic signaling peptide with observed biological activity at nanomolar concentrations (KD ~2.4 nM) in preclinical CNS models. While not a controlled substance, its CNS-active peptide classification and lack of established human safety data warrant cautious laboratory handling. No acute toxicity data is available for this specific variant.

Handling Precautions:

• Handle under standard laboratory conditions using nitrile gloves, eye protection, and a lab coat; avoid skin contact and inhalation of powder during weighing or reconstitution
• Reconstitution and aliquoting should be performed in a clean, controlled environment to prevent contamination
• No specific biosafety cabinet requirement for routine handling, though institutional biosafety protocols take precedence
• Avoid uncontrolled exposure; in the event of skin or eye contact, flush with water and follow institutional first-response procedures

Storage:

• Store lyophilized powder at −20°C, protected from light and moisture
• Avoid repeated freeze-thaw cycles; aliquot before freezing where feasible
• Reconstituted solutions should be used promptly and not stored long-term

Disposal:

• Dispose of unused compound and associated materials in accordance with institutional chemical waste protocols and applicable local regulations

No human safety profile has been established for this research-grade formulation. This compound is not approved for administration by any route.

Why Buy AC-Semax NH2 from Iron Mountain Labz?

Iron Mountain Labz provides the following quality and specification data for this product:

• Purity: ≥98% (HPLC)
• Assay Result: Confirmed to specification via reverse-phase HPLC analysis
• Appearance: White to off-white lyophilized powder; visually inspected per QC protocol
• Microbial Testing: Meets standard RUO microbial limits
• Endotoxin Levels: Tested; results available on request
• Certificate of Analysis (COA): Available upon request for each batch

For queries, complaints, or support, please contact help@ironmountainlabz.com 

FAQs

Q1: What is the regulatory status of AC-Semax NH2 in the United States? 

AC-Semax NH2 is not a scheduled controlled substance under the DEA Controlled Substances Act as of the time of writing. It is not approved by the FDA for any human or veterinary therapeutic use. It is classified as a research-grade peptide, available exclusively for in vitro and preclinical laboratory research conducted by qualified researchers at licensed institutions. 

Q2: What research applications has AC-Semax NH2 been investigated for in preclinical settings? 

In preclinical laboratory models, AC-Semax NH2 and its parent compound class have been investigated in relation to neurotrophic signaling, CNS neuroprotective pathway modulation, and melanocortin receptor pharmacology. Observed associations in animal models have included changes in BDNF and NGF expression in CNS tissue, as well as interactions with TrkB-linked intracellular cascades. 

Q3: How should AC-Semax NH2 be stored in a laboratory setting? 

For optimal stability, AC-Semax NH2 should be stored at −20°C in a moisture-free, light-protected environment. The lyophilized form is stable for up to 24 months under these conditions. Repeated freeze-thaw cycles should be avoided, as they may compromise peptide integrity. Once reconstituted for laboratory use, solutions should be used promptly, and any reconstitution protocols must conform to institutional laboratory safety standards.

Q4: Has AC-Semax NH2 been evaluated for safety in experimental conditions?

No human safety data has been established for this research-grade formulation. Preclinical animal studies involving Semax-class peptides have generally reported a favorable tolerability profile in the models studied; however, these findings are not directly applicable to research-grade synthetic analogues such as AC-Semax NH2, and institutional risk assessments should be conducted before any experimental use. All handling must comply with applicable occupational health and safety regulations.

Q5: How does AC-Semax NH2 differ structurally from standard Semax?:

Semax is an unmodified heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10). AC-Semax NH2 incorporates two structural modifications: N-terminal acetylation (Ac-) and C-terminal amidation (-NH₂). In preclinical plasma stability assays, these modifications have been investigated for their association with resistance to enzymatic degradation by endopeptidases and aminopeptidases, which has been observed to correlate with an extended half-life profile in experimental models relative to the unmodified parent peptide. Quantitative half-life comparison data specific to the AC-NH2 variant remain limited in peer-reviewed literature.

Q6: Is AC-Semax NH2 available in other concentrations or formats?:

Iron Mountain Labz offers AC-Semax NH2 in a 10mg lyophilized powder format. Researchers requiring information on batch availability, purity documentation, or related neuropeptide analogues available through Iron Mountain Labz may contact help@ironmountainlabz.com for current inventory and specification details.

References

Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of ACTH(4-7), regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54–60. PMID: 16962074. https://pubmed.ncbi.nlm.nih.gov/16962074/ 

Gudasheva TA, Antipova TA, Konstantinopolsky MA, Seredenin SB. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. European Journal of Pharmacology. 2006;536(3):258–262. PMID: 16635254. https://pubmed.ncbi.nlm.nih.gov/16635254/